Form 4: Brainstorm Cell Therapeutics CEO Acquires 15,000 Shares

Chaim Lebovits, President and CEO of Brainstorm Cell Therapeutics, recently acquired 15,000 shares of common stock at an average price of $0.5183.

Summary

• On May 28, 2024, Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., acquired 15,000 shares of the company's common stock.
• The shares were purchased at a weighted average price of $0.5183, with individual transaction prices ranging from $0.5161 to $0.5194.
• Following the transaction, Lebovits directly owns 1,164,865 shares and may be deemed the beneficial owner of an additional 2,000,847 shares held indirectly through ACCBT Corp. and ACC International Holdings Ltd.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the document itself is simply a regulatory filing.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's performance and future prospects. CEO's buying shares can be seen as a positive sign.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Chaim Lebovits, Stock Acquisition, SEC Form 4, Insider Trading